In their systematic review and meta-analysis, 1 Takagi et al concluded that abdominal aortic aneurysm (AAA) screening in 64-year-old men reduces both all-cause and AAA-related mortalities. They claimed their results extended the findings of a systematic evidence review for the US Preventive Services Task Force (USPSTF), 2 which concluded that a 1-time invitation for AAA screening in 65-year-old men was associated with decreased AAA rupture and AAA-related mortality but had little effect on all-cause mortality.
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The USPSTF did indeed recommend a 1-time screening for AAA with ultrasonography in men aged 65 to 75 years (B recommendation), but only for those patients who had ever smoked. 3 Abdominal aortic aneurysms are most prevalent in men who have ever smoked, occurring in approximately 6% to 7% of this population. 3 In contrast, AAAs occur only in about 2% of men aged 65 to 75 years who never smoked. 3 Consequently, the USPSTF recommended that clinicians should offer screening for AAA in men aged 65 to 75 years who have never smoked only selectively (C recommendation), 3 taking into account the patient's risk factors and the potential for harm (due to overdiagnosis and overtreatment). Risk factors such as older age, a first-degree relative with an AAA, a history of other vascular aneurysms, the presence of coronary artery disease, cerebrovascular disease, atherosclerosis, hypercholesterolemia, obesity, and hypertension would justify screening in a 65-to 75-year-old nonsmoker. In contrast, factors associated with a reduced AAA risk include African American race, Hispanic ethnicity, and diabetes mellitus. Given that even elective treatment is associated with perioperative mortality that can be as high as 5%, 4, 5 overtreatment is an important issue to consider when deciding whether or not to offer screening.
A recent article debating the benefits of AAA screening programs reported that for every 10 000 men invited to attend, 46 avoid dying from a ruptured AAA. 6 For every avoided death, however, 4 men were diagnosed with an AAA that would otherwise never have been detected or caused health problems in their lifetime. These patients have been overdiagnosed, with the potential to cause physical and psychological harm. 6 It is important to consider all available data in order to avoid reaching misleading conclusions. As the authors themselves mention, 1 there is a marked reduction in the incidence of AAAs around the world which is mainly attributed to the reduction in the prevalence of smoking. 7, 8 Another reason for the reduction in AAAs may be the diabetes epidemic 9, 10 ; a large (160 391 diabetic patients and 646 710 matched controls), population-based, cohort study showed a reduced incidence of AAAs in diabetic patients. 10 Given the reduction in the population prevalence of AAAs, as well as the marked difference in the prevalence of AAAs between smokers and nonsmokers, 3 it may be misleading to suggest that we can "make screening great again." 
